PAQR8 and breast cancer: We first used CRISPR-cas9 to delete PAQR8 in the triple-negative human breast cancer cell line SUM159, which expresses high endogenous levels of PAQR8. Colony formation assays were then performed in which PAQR8-KO and control SUM159 cells were treated with doxorubicin or docetaxel.